# Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

> **NCT03086642** · PHASE1 · COMPLETED · sponsor: **Karie D. Runcie, MD** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Talimogene laherparepvec

## Key facts

- **NCT ID:** NCT03086642
- **Lead sponsor:** Karie D. Runcie, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2021-05-13
- **Final completion:** 2022-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086642, "Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03086642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*